Motavizumab, A Neutralizing Anti-Respiratory Syncytial Virus (Rsv) Monoclonal Antibody Significantly Modifies The Local And Systemic Cytokine Responses Induced By Rsv In The Mouse Model

Motavizumab (MEDI-524) is a monoclonal antibody with enhanced neutralizing activity against RSV. In mice, motavizumab suppressed RSV replication which resulted in significant reduction of clinical parameters of disease severity. We evaluated the effect of motavizumab on the local and systemic immune...

Descripció completa

Guardat en:
Dades bibliogràfiques
Autors principals: Mejías, Asunción, Chávez-Bueno, Susana, Raynor, Martin B, Connolly, John, Kiener, Peter A, Jafri, Hasan S, Ramilo, Octavio
Format: Artigo
Idioma:Inglês
Publicat: BioMed Central 2007
Matèries:
Short Report
Accés en línia:https://ncbi.nlm.nih.gov/pmc/articles/PMC2222633/
https://ncbi.nlm.nih.gov/pubmed/17961258
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/1743-422X-4-109
Etiquetes: Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!

Ítems similars